Clinical Significance of Angiogenesis in Gastrointestinal Cancers: a Target for Novel Prognostic and Therapeutic Approaches

Overview

Journal Ann Surg

Specialty General Surgery

Date 2003 Jul 2

PMID 12832961

Citations 36

Authors

Ronnie Tung-Ping Poon

Sheung-Tat Fan

John Wong

Affiliations

Soon will be listed here.

Abstract

Objective: To review the current data on the prognostic and therapeutic implications of tumor angiogenesis in gastrointestinal cancers.

Summary Background Data: Numerous studies have evaluated the prognostic value of tumor angiogenesis and the potential role of antiangiogenic therapy in various gastrointestinal cancers.

Methods: A Medline literature search was conducted using "angiogenesis" or the names of various angiogenic factors in combination with the names of gastrointestinal cancers as the key words.

Results: Several studies have demonstrated a significant prognostic impact of tumor microvessel density and tumor expression of angiogenic factors, in particular vascular endothelial growth factor (VEGF), in various gastrointestinal cancers. A few studies have suggested that circulating VEGF might be a useful prognostic marker. However, results were not consistent across all studies and were limited by the retrospective nature of most studies. Antiangiogenic therapy has been shown to be effective against all common gastrointestinal cancers in preclinical studies, but currently there are few clinical data with regard to antiangiogenic therapy in gastrointestinal cancers.

Conclusions: There is mounting evidence to suggest that assessment of tumor angiogenesis might provide a novel approach of prognostication in patients with gastrointestinal cancers. However, current results from retrospective studies need to be validated by prospective studies. Antiangiogenic therapy is a promising strategy of cancer treatment that might be particularly useful in combination therapy for unresectable cancers or as an adjuvant therapy for resectable tumors.

Citing Articles

Triptolide suppresses IL-1β-induced expression of interleukin-8 by inhibiting ROS-Mediated ERK, AP-1, and NF-κB molecules in human gastric cancer AGS cells.

Li S, Sah D, Arjunan A, Ameer M, Lee B, Jung Y Front Oncol. 2025; 14:1498213.

PMID: 39950099 PMC: 11821500. DOI: 10.3389/fonc.2024.1498213.

Protective Effect of Daidzein against Diethylnitrosamine/Carbon Tetrachloride-Induced Hepatocellular Carcinoma in Male Rats.

Bashandy S, Ebaid H, Al-Tamimi J, Hassan I, Omara E, Elbaset M Biology (Basel). 2023; 12(9).

PMID: 37759583 PMC: 10525464. DOI: 10.3390/biology12091184.

An emerging research: the role of hepatocellular carcinoma-derived exosomal circRNAs in the immune microenvironment.

Xu H, Lin X, Xu Y, Xue H, Lin S, Xu T Front Immunol. 2023; 14:1227150.

PMID: 37753074 PMC: 10518420. DOI: 10.3389/fimmu.2023.1227150.

Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.

Pinto E, Pelizzaro F, Farinati F, Russo F Medicina (Kaunas). 2023; 59(6).

PMID: 37374319 PMC: 10305396. DOI: 10.3390/medicina59061115.

The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma.

Oura K, Morishita A, Hamaya S, Fujita K, Masaki T Int J Mol Sci. 2023; 24(3).

PMID: 36769116 PMC: 9917861. DOI: 10.3390/ijms24032805.

References

Ogura O, Takebayashi Y, Sameshima T, Maeda S, Yamada K, Hata K . Preoperative assessment of vascularity by color Doppler ultrasonography in human rectal carcinoma. Dis Colon Rectum. 2001; 44(4):538-46; discussion 546-8. DOI: 10.1007/BF02234326. View

Ker C, Chen H, Juan C, LO H, Shen Y, Chen J . Role of angiogenesis in hepatitis and hepatocellular carcinoma. Hepatogastroenterology. 1999; 46(26):646-50. View

Kakeji Y, Maehara Y, Sumiyoshi Y, Oda S, Emi Y . Angiogenesis as a target for gastric cancer. Surgery. 2002; 131(1 Suppl):S48-54. DOI: 10.1067/msy.2002.119304. View

OReilly M, Holmgren L, Chen C, Folkman J . Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996; 2(6):689-92. DOI: 10.1038/nm0696-689. View

Kwak B, Shim H, Park E, Kim S, Choi D, Lim H . Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography. Invest Radiol. 2001; 36(8):487-92. DOI: 10.1097/00004424-200108000-00008. View

Takatsuka S, Yamada N, Sawada T, Ogawa Y, Maeda K, Ohira M . Contribution of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis. Int J Oncol. 2000; 17(2):253-8. DOI: 10.3892/ijo.17.2.253. View

Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, Yamazaki Y . Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer. 2001; 92(7):1788-97. DOI: 10.1002/1097-0142(20011001)92:7<1788::aid-cncr1695>3.0.co;2-z. View

Zhou J, Tang Z, Fan J, Wu Z, Li X, Liu Y . Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol. 2000; 126(1):57-61. DOI: 10.1007/s004320050009. View

Shaheen R, Tseng W, Davis D, Liu W, Reinmuth N, Vellagas R . Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 2001; 61(4):1464-8. View

10.

Poon R, Fan S, Wong J . Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001; 19(4):1207-25. DOI: 10.1200/JCO.2001.19.4.1207. View

11.

Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler M . Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997; 3(8):1309-16. View

12.

Folkman J, Browder T, Palmblad J . Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost. 2001; 86(1):23-33. View

13.

Werther K, Christensen I, Brunner N, Nielsen H . Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol. 2000; 26(7):657-62. DOI: 10.1053/ejso.2000.0977. View

14.

Kamiya K, Konno H, Tanaka T, Baba M, Matsumoto K, Sakaguchi T . Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody. Jpn J Cancer Res. 1999; 90(7):794-800. PMC: 5926128. DOI: 10.1111/j.1349-7006.1999.tb00817.x. View

15.

Etoh T, Shibuta K, Barnard G, Kitano S, Mori M . Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res. 2000; 6(9):3545-51. View

16.

Li X, Tang Z, Qin L, Zhou J, Sun H . Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2000; 18(4):511-7. View

17.

Banner B, Whitehouse R, Baker S, Swanson R . Tumor angiogenesis in stage II colorectal carcinoma: association with survival. Am J Clin Pathol. 1998; 109(6):733-7. DOI: 10.1093/ajcp/109.6.733. View

18.

Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M . An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res. 2001; 20(6B):4489-93. View

19.

Chow N, Hsu P, Lin X, Yang H, Chan S, Cheng K . Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol. 1997; 28(6):698-703. DOI: 10.1016/s0046-8177(97)90179-9. View

20.

Takahashi Y, Cleary K, Mai M, Kitadai Y, Bucana C, Ellis L . Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996; 2(10):1679-84. View